A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...

Full description

Bibliographic Details

Published in:	Acta Pharmaceutica Sinica B
Main Authors:	Yan Li, Ya Chu, Guangjiang Shi, Xiaobin Wang, Wanli Ye, Chun Shan, Dajia Wang, Di Zhang, Wei He, Jingwei Jiang, Shuqian Ma, Yuhong Han, Zhili Zhao, Shijia Du, Zhen Chen, Zhiyu Li, Yong Yang, Chen Wang, Xi Xu, Hongxi Wu
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Subjects:	Drug resistance Enzalutamide Castration-resistant prostate cancer Androgen receptor splice variant 7 Heterodimers Degradation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383522002106